Eton Pharmaceuticals, Inc. (ETON)
Eton Pharmaceuticals, Inc. (ETON) from its SEC filings: 2025 revenue $80.0 million (+105% vs the year before), net margin -6%, free cash flow $10.2 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $80.0 million |
| Revenue growth | +105% |
| Net income | -$4.6 million |
| Net margin | -5.8% |
| Free cash flow | $10.2 million |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +99% |
| Cash | $26.8 million |
| Long-term debt | $19.1 million |
| Share count, 1 year | +7% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.